In the claims:

Please amend the claims as follows:

1. (original). A method of inhibiting the growth of cancer cells comprising exposing cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and a retinoid, wherein said retinoid is associated with lipid carrier particles.

2. (original). The method of Claim 1 wherein the retinoid is retinoic acid.

3. (original). The method of Claim 2 wherein the retinoic acid is all-trans retinoic acid.

4. (previously amended) The method of Claim 1 wherein the lipid carrier particles comprise all-trans retinoic acid, lipid, and a triglyceride: wherein a molar ratio of retinoid to lipid is at least about 15:85; the triglyceride is at least about 15% by weight of the composition; and the composition is stable in an aqueous environment.

5. (previously amended) The method of Claim 1 comprising administering said retinoid composition by intravenous infusion.

6. (previously amended) The method of Claim 1 wherein the composition comprising at least one interferon and a retinoid is administered at a frequency from daily to about 3 out of 7 days per week.

7. (canceled). The method of Claim 1 wherein the cancer is a renal cancer.

8. (previously amended). A method of inhibiting the growth of cancer cells comprising co-timely exposing cancerous cells to: a) a therapeutically effective amount of a composition which comprises at least one interferon and b) a therapeutically effective amount of a retinoid, wherein said retinoid is associated with lipid carrier particles.

9. (currently amended) A therapeutic treatment kit for the treatment of cancer comprising interferon, all-trans retinoic acid <u>associated with lipid carrier particles</u> and instructional

materials for the combined use of said all-trans retinoic acid associated with lipid carrier particles and interferon.

10. (previously added) The method of Claim 1 wherein the cancer is selected from the group consisting of renal cancer, breast cancer, head cancer, and neck cancer.

11. (previously added) The method of Claim 8 wherein the cancer is selected from the group consisting of renal cancer, breast cancer, head cancer, and neck cancer.

12. (previously added) The method of Claim 1 wherein the cancerous cells are exposed in vivo.

13. (previously added) The method of Claim 8 wherein the cancerous cells are exposed in vivo.

14. (previously added) The method of Claim 1, wherein the interferon is selected from the group consisting of alpha, beta, and gamma interferon.

15. (previously added) The method of Claim 14, wherein the interferon is alpha interferon.

16. (previously added) The method of claim 15, wherein alpha interferon is administered in an amount of about 1 to about 25 million IU.

17. (previously added) The method of claim 3, wherein the amount of all-trans retinoic acid is about 15-300 mg/m^2.

18. (previously added) The method of claim 17, wherein the amount of all-trans retinoic acid is about 15 mg/m^2.

19. (previously added) The method of Claim 8, wherein the interferon is selected from the group consisting of alpha, beta, and gamma interferon.

20. (previously added) The method of Claim 19, wherein the interferon is alpha interferon.

21. (previously added) The method of claim 20, wherein alpha interferon is administered in an amount of about 1 to about 25 million IU.

22. (previously added) A method of inhibiting the growth of cancer cells, wherein the cancer cells are selected from the group consisting of renal, head, neck, and breast cancer cells, comprising exposing said cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and a retinoid, wherein the retinoid is all-trans retinoic acid and is associated with lipid carrier particles.

23. (previously added) The method of claim 22 wherein the interferon is selected from the group consisting of alpha, beta, and gamma interferon.

24. (previously added) The method of claim 23 wherein the interferon is alpha interferon.

25. (previously added) The method of claim 24, wherein alpha interferon is administered in an amount of about 1 to about 25 million IU.

26. (previously added) The method of claim 22, wherein the amount of all-trans retinoic acid is about 15-300 mg/m^2.

27. (previously added) The method of claim 26, wherein the amount of all-trans retinoic acid is about 15 mg/m^2.

28. (previously added) A method of inhibiting the growth of cancer cells, wherein the cancer cells are selected from the group consisting of renal, head, neck, and breast cancer

cells, comprising exposing said cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and a retinoid, wherein the retinoid is all-trans retinoic acid and is associated with lipid carrier particles and the at least one interferon is alpha interferon.

29. (previously added) The method of Claim 4 wherein the cancer is a renal cell cancer.

30. (previously added) The method of Claim 10 wherein the cancer is a renal cell cancer.

31. (previously added) The method of Claim 11 wherein the cancer is a renal cell cancer.

32. (previously added) The method of claim 16, wherein alpha interferon is administered in an amount of about 3 to about 5 million IU.

33. (previously added) The method of claim 21, wherein alpha interferon is administered in an amount of about 3 to about 5 million IU.

34. (previously added) The method of claim 25, wherein alpha interferon is administered in an amount of about 3 to about 5 million IU.

35. (new) The method of claim 8, wherein said retinoid is all trans-retinoic acid.

36. (new) The method of claim 8, wherein the lipid carrier particles comprise all-trans retinoic acid, lipid, and a triglyceride: wherein a molar ratio of retinoid to lipid is at least about 15:85; the triglyceride is at least about 15% by weight of the composition; and the composition is stable in an aqueous environment.

37. (new) The therapeutic treatment kit of claim 9, wherein said interferon is alpha interferon.

38. (new) The therapeutic treatment kit of claim 9, wherein the lipid carrier particles comprise all-trans retinoic acid, lipid, and a triglyceride: wherein a molar ratio of retinoid to lipid is at least about 15:85; the triglyceride is at least about 15% by weight of the composition; and the composition is stable in an aqueous environment.

39. (new) A therapeutic treatment kit for the treatment of cancer comprising interferon, a retinoid associated with lipid carrier particles and instructional materials for the combined use of said retinoid associated with lipid carrier particles and interferon.

40. (new) The method of claim 22, wherein the lipid carrier particles comprise all-trans retinoic acid, lipid, and a triglyceride: wherein a molar ratio of retinoid to lipid is at least about 15:85; the triglyceride is at least about 15% by weight of the composition; and the composition is stable in an aqueous environment.

41. (new) The method of claim 22, wherein the cancer cells are renal cancer cells.

42. (new) The method of claim 28, wherein the lipid carrier particles comprise all-trans retinoic acid, lipid, and a triglyceride: wherein a molar ratio of retinoid to lipid is at least about 15:85; the triglyceride is at least about 15% by weight of the composition; and the composition is stable in an aqueous environment.

43. (new) The method of claim 28, wherein the cancer cells are renal cancer cells.

44. (new) The method of claim 28, wherein the cancerous cells are exposed in vivo.

45. (new) The method of claim 28, wherein alpha interferon is administered in an amount of about 1 to about 25 million IU.

46. (new) The method of claim 45, wherein alpha interferon is administered in an amount of about 3 to about 5 million IU.

47. (new) The method of claim 28, wherein the amount of all-trans retinoic acid is about 15-300 mg/m^2.

48. (new) The method of claim 47, wherein the amount of all-trans retinoic acid is about 15 mg/m^2.